Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis, "Beyond the Abstract," by Jay P. Ciezki, MD

Tweet

BERKELEY, CA (UroToday.com) - The recently reported Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSPC) trials have led to a widely hyped but short-sighted and potentially dangerous conclusion about the use of prostate-specific antigen (PSA) screening-based screening for prostate cancer. To read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.